From the desk of J. D. Faccinetti, co-founder – We are big fans; collaboration works. Our experience and research suggest that when collaboration between organizations is strong, learning improves, and outcomes…
Industry News
News from pharmaceutical companies and other related healthcare organizations
The endocrine world gathers in Chicago
June 20, 2023
By J D Faccinetti, co-founder – In a three-day conference packed with thousands of scientists, endocrinologists, industry, and researchers, ENDO 2023 Conference presented a comprehensive review of the latest in pituitary disease advances, treatment, management, developments,
Acroline™ – Helping you live well with Acromegaly
November 9, 2022
Acroline™ is a series of four brochures created by Pfizer in collaboration with an international panel of people with acromegaly, acromegaly support groups, and health psychologists. This series of supportive guides and tools are designed to help keep your life on track and live well with acromegaly.
Another great support resource for people with acromegaly
October 27, 2022
We take advantage of Acromegaly Day, coming up on November 1, to highlight resources from industry partners. The Pfizer Patient Affairs Liaisons (PALs) connect patients and caregivers affected by rare conditions with programs and information. PALs work with
Recordati Rare Diseases provides access to the LINC 4 study in the Journal of Clinical Endocrinology and Metabolism (JCEM).
June 22, 2022
This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,
A conversation with Amryt’s new president for the Americas, Sheila Frame
June 7, 2022
We caught up with Sheila a few weeks ago at the Acromegaly Community Conference near San Francisco. We had a captivating chat about Mycapssa (oral octreotide) and about Amryt’s start in Dublin, Ireland, just six years ago, its philosophy, brand, and plans.
Good news from Amryt for acromegaly patients in Europe
March 22, 2022
Amryt Pharma announced positive results for the MPOWERED phase 3 trial for Mycapssa® oral octreotide for acromegaly patients, in a recent press release. The trial paves the way for the approval of Mycapssa® by the EMA.
Corcept’s Grace Study for a new Cushing’s drug; an update
February 22, 2022
The Corcept Therapeutics “Grace Study”, designed to evaluate the benefits and side effects of a new medication for people with endogenous Cushing’s syndrome, continues full steam ahead. The company recently announced the availability of new
Emotional wellness with acromegaly
September 7, 2021
Kudos to Pfizer’s new series on patient support. The first one features critical advice on emotional and mental help support! The materials provide valuable content given the importance of mental health issues to acromegaly patients.
Big news for acromegaly at Crinetics
July 12, 2021
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
Two clinical trials for acromegaly patients: see if you are eligible.
May 10, 2021
Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers
The Road to MYCAPSSA: A Conversation with Dr. Bill Ludlam
January 26, 2021
We recently had a chance to sit down with Chiasma Inc.’s Senior VP of Clinical Development & Medical Affairs, Dr. Bill Ludlam, to discuss his career and his work in rare diseases. Dr. Ludlam played
Hello, Pills!
September 7, 2020
With the recent approval and commercial launch of MYCAPSSA®, Chiasma delivers the first and only oral somatostatin analog to treat acromegaly. The research showed 58% of patients maintained normal IGF-1 levels with the new oral